European heart journal · 2019
Transcatheter heart valve interventions: where are we? Where are we going?
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Prendergast Bernard D, Baumgartner Helmut, Delgado Victoria, Gérard Olivier, Haude Michael, Himmelmann Anders, Iung Bernard, Leafstedt Matthew, Lennartz Jasmine, Maisano Francesco, Marinelli Elena Andreassi, Modine Thomas, Mueller Markus, Redwood Simon R, Rörick Olaf, Sahyoun Cherif, Saillant Erika, Søndergaard Lars, Thoenes Martin, Thomitzek Karen, Tschernich Marion, Vahanian Alec, Wendler Olaf, Zemke Evelyn Julia, Bax Jeroen J
Аннотация
Transcatheter heart valve interventions have transformed the outcomes of patients with valvular heart disease (VHD) who are unfavourable candidates for surgery. Technological advances have allowed extension of these interventions to younger or lower risk patients and those with other forms of VHD and may in the future permit earlier treatment of VHD in less symptomatic patients or those with moderate disease. The balance of risks and benefits is likely to differ between lower and higher risk patients, and more evidence is needed to evaluate the net benefit of transcatheter technology in these groups. As academic researchers, clinicians, industry, and patient stakeholders collaborate to research these broader indications for transcatheter valve interventions, it is essential to address (i) device durability and deliverability, (ii) specific anatomical needs (e.g. bicuspid aortic valves, aortic regurgitation, mitral and tricuspid valve disease), (iii) operator training, and (iv) the reinforced importance of the multidisciplinary Heart Team.